HOP homeoboxGenealiases: CAMEO · HOD · HOP · LAGY · NECC1 · OB1
Q-omics provides the consensus-scored HOPX profile across patient tissues and cancer cell-line models. HOPX expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HOPX is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, HOPX protein abundance shows 30,307 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, HNSC, and PDAC as cancer lineages where HOPX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOPX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOPX survival associations across molecular data types. HOPX RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOPX RNA expression–survival associations across cancer types. High HOPX expression shows unfavorable associations in KIRP, UVM, LGG and LAML, but favorable associations in SKCM and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HOPX RNA expression.
This table summarizes HOPX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HOPX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOPX shows lower tumor expression in HNSC, KICH, LUAD and LUSC and higher tumor expression in BRCA and LIHC. The HNSC box plot shows higher HOPX RNA expression in normal versus tumor tissue (log2 FC = −2.720, t-test p < 0.001).
This table shows molecular features associated with HOPX in patient tissues and cancer cell lines. In patient samples, HOPX shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, HOPX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_NSCLC_LUAD.
